wildpixel/iStock via Getty Images
Sesen Bio, Inc. (SESN) suffered a setback in Q3 2021 after the US Food and Drug Administration (FDA) failed to approve its Biologics License Application (BLA) for Vicineum. The FDA questioned the current form of Vicineum…
Sesen Bio: Hoping For An Easy Revalidation Of Vicineum By 2022
Share this article
More News


Crypto, Stocks Rally Post-Rate Hike; Zcash Hits All-Time High
September 18, 2026

FCA Targets Three More London Sites Over Unregistered P2P Crypto Trading
September 18, 2026


Emirates accepts crypto payments for UAE flight bookings
September 18, 2026

Would You Want CRM Stock Back At The Price It Just Left?
September 18, 2026
